Freenome Presents Data Revealing Signatures of Immune Checkpoint Inhibitor Treatment Response Found to Be Common Across Kidney, Melanoma, and Lung Cancers
Freenome demonstrates potential for patient stratification and monitoring using its multiomics platform at the American Association for Cancer Research (AACR) Annual Meeting
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–#aacr21–Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection using a routine blood draw, today announced results of an analysis revealing the potential to use its platform for patient stratification and monitoring. Plasma samples from patients with kidney (n=21), melanoma (n=14) or non-small cell lung cancer (n=91) revealed signatures of immune checkpoint inhibition treatment response found to be common across all three cancer types. Whole-genome cell-free DNA (cfDNA) sequencing identified 13 transcription factors and 269 genes that reveal a potential pathway of treatment resistance and a possible epithelial mesenchymal transition signature in responders. A subsequent longitudinal analysis on a subset of lung cancer patients also identified markers for treatment response.
“These results show the promise of our multiomics platform, which combines signatures from both tumor- and non-tumor-derived sources,” commented Mike Nolan, Chief Business Officer of Freenome. “A blood-based test that can predict and monitor treatment response would help address the clear need for improved biomarkers for cancer patients undergoing immune checkpoint inhibitor treatment, where responses are highly variable.”
“This work further demonstrates the many applications of our multiomics platform, and highlights our commitment to understanding the full potential of cfDNA,” commented C. Jimmy Lin, M.D., Ph.D., M.H.S., Chief Scientific Officer at Freenome. “Inferring nucleosome positioning through cfDNA is yet another way we can provide more insight to answer research questions and, ultimately, apply this to clinical questions that are integral to patient care.”
Data were presented in a poster presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting. The poster is available online at https://www.freenome.com/science.
Freenome is a biotechnology company that has pioneered the most comprehensive multiomics platform for early cancer detection using a routine blood draw, beginning with a colorectal cancer screening test. The company combines its deep expertise in molecular biology with advanced computational biology and machine learning techniques to detect disease-associated patterns among billions of circulating cell-free biomarkers. Freenome is also building a machine learning feedback loop with healthcare providers to leverage real-world data and improve patient care through early detection. Freenome is headquartered in South San Francisco, California.